#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Intracranial germ cell tumour Follicle centre lymphoma follicular grade I II – III refractory Fusarium infection Noonan syndrome Chronic myeloid leukaemia Small cell lung cancer extensive stage Primary biliary cholangitis Neonatal asphyxia Intracranial calcification HER2 gene amplification Restless legs syndrome Thymic carcinoma Cerebral amyloid angiopathy Undifferentiated sarcoma Osteogenesis imperfecta More trials…

    Learn about Rare Diseases

    Niemann-Pick disease – Basic Information Mucopolysaccharidosis II – Life with Disease Krabbe’s disease – Life with Disease Lymphangioma – Diagnostics Piriformis syndrome – Diagnostics Antithrombin III deficiency Splenic marginal zone lymphoma – Diagnostics Ewing’s sarcoma recurrent Glycogen storage disease type V – Treatment Rhabdomyosarcoma recurrent More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    VANDETANIB VTX2735 SODIUM Auto4 Interferon Alfa A52 Roginolisib Cangrelor Tetrasodium Thymalfasin GRNA1599 Eptinezumab ZIMISLECEL Pegcetacoplan Aluminium Oxide, Hydrated Epinephrine AZD6234 Aluminium Oxide Lactose Acenocoumarol Cilazapril Milnacipran Hydrochloride More therapies…

    Learn about Your Condition

    Small for dates baby Cervix carcinoma Brain stem glioma Schizophrenia Albright's disease Arthralgia Ewing's sarcoma metastatic Drug eruption Osteosarcoma metastatic Myositis Renal cancer Tendon rupture Wiskott-Aldrich syndrome Cervix carcinoma stage I Malignant lymphoid neoplasm More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Hormone-dependent prostate cancer

  • Study on Lutetium-177-PSMA and 18F-PSMA-1007 for Patients with Oligo-metastatic Hormone Sensitive Prostate Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • 18F-Psma-1007
    • Lutetium (177Lu) Vipivotide Tetraxetan
    Cyprus The Netherlands

  • Study Comparing 177Lu-PSMA-617 with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • Buserelin Acetate
    • Flutamide
    • Nilutamide
    Austria Belgium Czechia Denmark France Germany +4

  • Study comparing darolutamide versus hormone therapy (goserelin, leuprorelin, triptorelin, degarelix) in men with untreated hormone-sensitive prostate cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • Triptorelin Pamoate
    • Goserelin Acetate
    • Darolutamide
    Belgium France Italy Spain

  • Study of Capivasertib and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer with PTEN Deficiency

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • Abiraterone Acetate
    • Capivasertib
    Belgium Bulgaria Czechia France Germany The Netherlands +3

  • Study Comparing Docetaxel, Darolutamide, and ADT for Patients with Metastatic Hormone-Sensitive Prostate Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Buserelin Acetate
    • Goserelin Acetate
    • Relugolix
    Austria Germany

  • Study of luxdegalutamide and abiraterone combination in adult men with metastatic hormone-sensitive prostate cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • LUXDEGALUTAMIDE
    • Relugolix
    • Abiraterone
    Czechia France Germany Italy The Netherlands Poland +1
Previous Page
1 2 3

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!